Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cartesian Therapeutics Inc. (RNAC) Statistics
Cartesian Therapeutics (RNAC) has a market cap of $193.69M and an enterprise value of $126.84M. It kept -12435.22% of revenue as net income over the last 12 months. Its share count is up 16.56% from a year earlier.
Total Valuation
Enterprise value is 34.51% below the market cap, as cash exceeds debt.
| Market Cap | $193.69M |
|---|---|
| Enterprise Value | $126.84M |
| Latest price (Nov 17, 2026) | $6.12 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 181.0x.
| P/S Ratio | 181.0x |
|---|---|
| Forward P/S | 462.1x |
Price Statistics
The stock is down 17.96% over 52 weeks and trades 12.82% below its 50-day average.
| Beta (1Y) | 1.35 |
|---|---|
| 52-Week Change | -17.96% |
| 1-Month Change | +0.66% |
| 3-Month Change | -41.66% |
| 6-Month Change | +0.49% |
| 5-Year Change | -93.98% |
| 10-Year Change | -98.77% |
| Total Return (1Y) | -17.96% |
| Total Return (3Y CAGR) | -42.44% |
| Total Return (5Y CAGR) | -42.75% |
| Return vs SPY (1Y) | -31.24% |
| Max Drawdown (1Y) | -42.59% |
| Max Drawdown (3Y) | -85.58% |
| Sharpe Ratio (1Y) | -0.27 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $7.02 |
| 200-Day Average | $7.61 |
| 52-Week Range | $5.60 to $11.00 |
| RSI (14 Days) | 39.4 |
| Average Volume (20 Days) | 132.75K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.38x current liabilities.
| Current Ratio | 8.38x |
|---|---|
| Quick Ratio | 8.38x |
Returns and Efficiency
Return on invested capital is 147.21% over the last 12 months, against a 5-year average of 41.05%.
| Return on Assets (ROA) | -43.31% |
|---|---|
| Return on Invested Capital (ROIC) | 147.21% |
| ROA (5Y Average) | -25.70% |
| ROIC (5Y Average) | 41.05% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 8.27x |
Scores
RNAC has an Altman Z-Score of -4.89, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.89 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.02M over the last 12 months is down 6.05% from the 12 months before.
| Revenue | $1.02M |
|---|---|
| Revenue Growth (YoY) | -6.05% |
| Gross Profit | $1.02M |
| Operating Income | -$159.29M |
| Pretax Income | -$136.77M |
| Net Income | -$127.46M |
| EBITDA | -$135.74M |
| Reported EPS (TTM) | -$3.58 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $122.97M |
|---|---|
| Total Debt | $56.13M |
| Net Cash | $66.85M |
| Net Cash Per Share | $2.21 |
| Working Capital | $115.80M |
| Shareholder Equity | -$130.47M |
| Tangible Book Value | -$272.53M |
| Total Assets | $294.31M |
| Total Liabilities | $424.77M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.23M of capital spending, operating cash flow left -$89.89M of free cash flow.
| Operating Cash Flow | -$88.66M |
|---|---|
| Capital Expenditures | $1.23M |
| Free Cash Flow | -$89.89M |
| FCF Per Share | -$2.97 |
| Depreciation and Amortization | $2.79M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -15540.88%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -15540.88% |
| Pretax Margin | -13343.41% |
| Net Margin | -12435.22% |
| EBITDA Margin | -13243.02% |
| FCF Margin | -8770.05% |
Growth
Revenue fell 70.66% a year over 3 years.
| Revenue Growth (3Y CAGR) | -70.66% |
|---|---|
| Revenue Growth (5Y CAGR) | -29.96% |
Dividends and Yields
RNAC does not pay a dividend. Its free cash flow yield is -48.46%.
| FCF Yield | -48.46% |
|---|---|
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
Stock Splits
The last split was a 1-for-30 reverse split on Apr 5, 2024.
| Last Split Date | Apr 5, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 7 similar companies, RNAC has the 2nd highest P/S.
P/S RatioPeer median 4.3x
ROICPeer median -40.30%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -60.81%
| P/S Ratio | 181.0x vs 4.3x median |
|---|---|
| ROIC | 147.21% vs -40.30% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -6.05% vs -60.81% median |
Analyst Forecast
Consensus estimates put revenue growth at -68.04% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -68.04% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RNAC
What is RNAC's market cap?
Cartesian Therapeutics has a market cap of $193.69M. Its enterprise value, which adds debt and subtracts cash, is $126.84M.
How many shares of RNAC are outstanding?
Cartesian Therapeutics has 30.31M shares outstanding. The count is up 16.56% from a year earlier.
Does RNAC pay a dividend?
No. Cartesian Therapeutics does not pay a dividend.
How much debt does RNAC have?
Cartesian Therapeutics has $56.13M of total debt and $122.97M of cash and equivalents, a net cash position of $66.85M.
RNAC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors